GlassScriptPhysician profile
Edward J Wos
NPI 1457429680
$1,349.26
in general payments reported to CMS, 2019-2025
28 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $325 · 2021: $123 · 2022: $142 · 2023: $63.56 · 2024: $112 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.88 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $262.11 | 2019-2023 | |
| Pfizer INC. | $165.12 | 2019-2025 | |
| Lilly USA, LLC | $79.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $75.31 | 2021-2024 | Enhertu |
| Seagen INC. | $70.83 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $70.07 | 2022-2025 | |
| Celgene Corporation | $61.22 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $55.06 | 2019-2021 | |
| Incyte Corporation | $48.31 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.14 | 2019-2020 | |
| Daiichi Sankyo INC. | $46.05 | 2023-2025 | Datroway, Enhertu |
| Gilead Sciences, INC. | $43.39 | 2024-2025 | |
| Abbvie INC. | $40.28 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $37.86 | 2019-2020 | |
| Emd Serono, INC. | $31.66 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.51 | 2022-2024 | Alunbrig |
| Clovis Oncology, INC. | $29.12 | 2020 | |
| Glaxosmithkline, LLC. | $17.56 | 2023 | Shingrix |
| Epizyme, INC. | $17.12 | 2020 | |
| Recordati_rare_diseases_inc. | $15.98 | 2025 | Enjaymo |
| Rigel Pharmaceuticals, INC. | $15.90 | 2022 | |
| Immunomedics, INC. | $15.87 | 2020 | |
| Kite Pharma, INC. | $14.67 | 2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $13.54 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.21 | 2020 | |
| Astellas Pharma US INC | $11.57 | 2019 | |
| Shire North American Group INC | $11.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Wos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.